IRhythm Technologies Inc. (NASDAQ: IRTC) fell sharply after its November 5, 2026 third-quarter call even as adjusted profits jumped. On November 6 activist short seller Spruce Point Capital wrote that the call was "particularly bad," asked how the stock still trades at a premium multiple to med-tech peers, and said the VitalConnect deal looked "entirely defensive, expensive, and a band aid over an injured growth story." The open debate is whether record margins can outrun soft Zio AT demand and a delayed in-house MCT filing.
This is journalism and commentary, not investment advice. We hold no position unless stated.
Key facts
- Ticker: IRTC on Nasdaq; ambulatory cardiac monitoring (Zio patches) plus a newly closed MCT bolt-on.
- The call: Spruce Point reiterated a short framing after the Q3 call: premium valuation, defensive VitalConnect purchase, and growth that looks injured under the surface.
- Price basis: $130.19 prior close on November 5, 2026, the last close before Spruce Point's November 6 morning post.
- Q3 revenue: $221.6 million, up 14.9% year over year, per the call transcript.
- Margins: gross margin 74.2% (including about $3.1 million of tariff refunds); adjusted EBITDA margin 23.1%.
- Zio AT: roughly flat year over year; management tied the miss to customers deferring onboarding after the VitalConnect announcement.
- VitalConnect: closed October 5, 2026; about $16 million expected in Q4 revenue; Zio MCT FDA filing pushed into 2027.
- Guide: full-year 2026 revenue $890 million to $895 million; adjusted EBITDA margin 15.5% to 16.0%.
Did iRhythm's Q3 call break the growth story?
Not on the headline profit line. Adjusted net income was $27.8 million, or $0.82 per share, versus an adjusted loss a year earlier. The market reaction focused on the mix: Zio Monitor stayed solid while Zio AT stalled and management said new accounts do not want two separate integrations before VitalConnect is on one platform. Spruce Point's premium-multiple question lands on that mix, not on the adjusted EBITDA print alone.
Why are short sellers pressing IRTC now?
- Defensive deal read. Spruce Point says VitalConnect was a band-aid after repeated Zio MCT delays.
- Near-term AT drag. Management expects AT softness to linger while commercial teams train on the combined portfolio.
- Organic guide math. Bulls hear a raised full-year range; bears subtract the $16 million VitalConnect stub and see slower underlying Q4 growth.
- Legal cash. GAAP included a $50 million IP settlement charge; free cash flow was negative $11.5 million including that payment.
Who's making this call and why?
Spruce Point Capital is a forensic short shop founded by Ben Axler. After the call it argued the print reinforced a defensive, expensive acquisition over an injured growth story. The firm published a forensic report on IRTC in August 2025.
Track record. In our tracking Spruce Point is 11-6 on 17 scored calls at 180 days versus the S&P 500, with an average edge of about +10.4 points and a last-10 record of 6-4. See the scoreboard.
Other voices. Street notes after the print included BTIG cutting a target to $170 while keeping a Buy rating, per market summaries. That still frames a long case against Spruce Point's short.
Who disagrees?
Bulls point to Zio Monitor outperformance, new accounts contributing 51% of year-over-year volume growth, record adjusted EBITDA margin, and a path to about $1 billion of organic 2027 revenue with mid-teens Monitor growth. Management says VitalConnect fills live look-in and 30-day MCT use cases Zio AT does not cover, and that a single integrated platform should reopen deferred onboarding. Cash and marketable securities were $560.7 million at quarter end, with a new $300 million revolving facility dated November 3, 2026.
Other risks to the short:
- Margins first. If AT re-accelerates after integration, the "injured growth" label fades.
- Guide raise. Headline revenue and margin guides moved higher even with VitalConnect dilution in Q4.
- Evidence base. Management cites large comparative studies supporting Zio diagnostic yield.
What are the key facts to verify?
- Company Q3 release and call for revenue, margins, AT commentary and VitalConnect timing.
- Spruce Point's August 2025 forensic report versus today's reiteration.
- Q4 revenue excluding VitalConnect versus the implied organic path.
- FDA timeline language for Zio MCT in 2027 and any DOJ or warning-letter updates in the next 10-Q.
What would prove it right or wrong?
Signals the short framing is working:
- Organic growth stays near the low-teens while AT stays flat and VitalConnect fails to offset.
- Gross margin or adjusted EBITDA compresses as integration costs hit.
- Another slip in the Zio MCT filing path.
Signals it is fading:
- AT volumes re-accelerate once VitalConnect sits on one EHR workflow.
- Organic revenue holds mid-teens without another guide cut underneath the headline.
- Cash generation stays positive after one-time legal payments.
This is journalism and commentary, not investment advice. We hold no position unless stated.
